Healthstar Medical Development Co., Ltd (SHA: 603590), a Beijing-based pharmaceutical company, has announced the first patient dosing in a Phase III clinical study for its drug candidate KC1036, which is aimed at treating patients with advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks a significant milestone in the development of KC1036 as a potential new treatment option for this challenging disease.
KC1036 is a tyrosine kinase inhibitor (TKI) that targets AXL, VEGFR2, and FLT3, and is currently under investigation in multiple clinical studies for various types of digestive system tumors and thymic tumors. The drug candidate has shown promising results in existing clinical data, demonstrating outstanding anti-tumor activity and a favorable safety profile.
The initiation of the Phase III clinical study for KC1036 in ESCC underscores Healthstar Medical’s commitment to advancing innovative therapies for patients with limited treatment options and highlights the potential of KC1036 in improving patient outcomes.- Flcube.com
